Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: Results of the EMA 2000 trial

Annals of Hematology

Volumn 84, Issue 6, 2005, Pages 376-382

  Thomas, Xavier ^a   Elhamri, Mohamed ^a   Chelghoum, Youcef ^a   Reman, Oumedaly ^b   Arnaud, Philippe ^c   Raffoux, Emmanuel ^d   Le, Quoc Hung ^e   Tavernier, Emmanuelle ^a   Dombret, Hervé ^a   Michallet, Mauricette ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Centre de Gerontologie Georges CLEMENCEAU   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute myelogenous leukemia; Mitoxantrone; Relapse; Timed sequential chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTARABINE; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INFECTION; INJECTION; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFECTION; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID; LIFE TABLES; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; REMISSION INDUCTION; RISK; STOMATITIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20444475804     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1037-1     Document Type: Article

References (34)

1. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67:389-390
2. Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DAG (1987) Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. Cancer Treat Rep 71:161-163
3. Fujimoto S, Ogawa M (1982) Antitumor activity of mitoxantrone against murine experimental tumors: Comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol 8:157-161
4. Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in Beagle dogs; comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 66:1139-1143
5. Zbinden G, Beilstein AK (1982) Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. Toxicol Lett 11:289-297
6. Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183
7. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W (1988) Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22:205-210
8. Kano Y, Suzuki K, Akutsu M, Suda K (1992) Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 6:440-445
9. Thomas X, Archimbaud E (1997) Mitoxantrone in the treatment of acute myelogenous leukemia: A review. Hematol Cell Ther 39:163-174
10. Burke PJ, Karp JE, Braine HG, Vaughan WP (1977) Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 37:2138-2146
11. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ (1989) In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73:24-30
12. Geller RB, Burke PJ, Karp JE, Humphrey RL, Braine HG, Tucker RW, Fox MG, Zahurak M, Morrell L, Hall KL, Piantadosi SA (1989) Two-step timed sequential treatment for acute myelocytic leukemia. Blood 74:1499-1506
13. Martino R, Guardia R, Altes A, Sureda A, Brunet S, Sierra J (1999) Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: Results of the phase II GEMIA protocol. Haematologica 84:226-230
14. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ (1996) Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979-4989
15. Karp JE, Donehower RC, Dole GB, Burke PJ (1987) Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-beta-d-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. Blood 69:1134-1140
16. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11-18
17. Grant S, Arlin Z, Gewitz D (1991) Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 5:336-339
18. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P (1993) Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11:2002-2009
19. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC Jr, Beer M, Ahmed T (1997) A randomized trial of high- vs. standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 11:485-489
20. Thomas X, Cambier N, Taksin AL, Reman O, Vekhoff A, Pautas C, Leblond V, Soler-Michel P, Ecstein-Fraïssé E, Archimbaud E (2000) Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leuk Res 24:957-963
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of the acute myeloid leukemia: A report of the French-American-British (FAB) Cooperative Group. Ann Intern Med 103:620-625 1:STN:280:BiqA3critFA%3D
22. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ (1988) Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 2:403-412
23. World Health Organization 1979 WHO handbook for reporting results of cancer treatment. WHO offset publication No. 48 Geneva Switzerland
24. Alexander J, Dainish N, Berger HJ, Goldman L, Johnston D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL (1981) Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med 300:278-283
25. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819
26. Preisler HD (1978) Failure of remission induction in acute myelocytic leukemia. Med Pediatr Oncol 4:275-276
27. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
28. Seiter K, Feldman E, Beer M, Qureshi Z, Durani H, Lake D, Ahmed T (1995) Phase II study of high-dose mitoxantrone-based induction therapy in patients with acute myeloid leukemia. Blood 86:780a
29. Khalil A, Ciobanu N, Sparano JA, Gucalp R, Dutcher JP, Wiernik PH (1995) Pilot study of high-dose mitoxantrone and busulfan plus autologous bone marrow transplantation in patients with advanced malignancies. Bone Marrow Transplant 15:93-97
30. Mollgard L, Tidefelt U, Sundman-Engberg B, Lofgren C, Lehman S, Paul C (1998) High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: A pharmacokinetic and clinical study. Ther Drug Monit 20:640-645
31. Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D (1996) Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 14:2480-2485
32. Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M (1999) A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer 86:2246-2251
33. Shenkenberg TD, von Hoff DD (1986) Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med 105:67-81
34. Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Holmes F (1985) Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update. Invest New Drugs 3:117-121